

VIII

Article, "Drug Exporter to Quit Trade," from the Washington Post, Jan. 28, 1972	Page 15259
Article, "New Drug Agency to Fight Pushers on Lower Levels," by Robert M. Smith, from the New York Times, Jan. 19, 1972	15260
Article, "United States Acts to Block Amphetamines From Mexico," by Harold M. Schmeck, Jr., from the New York Times, Jan. 19, 1972	15261
Article, "Pennwalt Division's License to Export Amphetamine Challenged by Justice Unit," from the Wall Street Journal, Jan. 19, 1972	15262
Letter dated May 15, 1972, to Isaac R. McGraw, II, vice president, Pennwalt Corp., from John S. Canavis, Centre European de Recherches Therapeutiques Appliquees, S.A.	15263
Letter dated June 27, 1972, to Dr. Saverio Mecca, Eufarma, Firenze, Italy, from Isaac R. McGraw, II, vice president, Pennwalt Corp.	15266

MATERIAL FROM FOOD AND DRUG ADMINISTRATION FILES ON BIPHETAMINE AND IONAMINE

Summary of New Drug Application No. 11-613 by L. L. Phillips, Ph. D., original application date Dec. 2, 1957	15267
Memorandum dated Aug. 13, 1958, to Dr. DeFelica, New Drug Branch, from E. I. Goldenthal, Division of Pharmacology, Food and Drug Administration	15268
Memorandum dated Feb. 17, 1959, to Dr. DeFelice, New Drug Branch, from E. I. Goldenthal, Division of Pharmacology, Food and Drug Administration	15269
Memorandum dated Jan. 16, 1964, to Dr. A. G. Pleron, Division of New Drugs, from Dr. William D'Aguanna, Division of Pharmacology, Food and Drug Administration	15269
Memorandum dated Oct. 29, 1965, to Dr. F. O. Kelsey, Division of New Drugs, from Dr. S. Hsia, Drug Review Branch, Food and Drug Administration	15269
Memorandum of telephone interview dated Dec. 8, 1967, between R. G. Rothwell, M.D., medical director, Strassenburgh Laboratories, and Robert M. Hodges, M.D., Director, Office of New Drugs, Food and Drug Administration	15270
Letter dated Aug. 28, 1969, to Strassenburgh Laboratories, Rochester, N. Y., from Robert O. Knox, M.D., Medical Officer, Food and Drug Administration	15270
New drug application Nos. 10-093, 11-538, and 11-613, July 1972	15272
Memorandum dated Aug. 30, 1972, to Barrett Scoville, M.D., Division of Neuropharmacological Drug Products, from Walter Sloboda, Division of Statistic Evaluation Branch, Food and Drug Administration	15273
Medical Summary of New Drug Application No. 11-613 by Theresa T. Woo, M.D., Nov. 28, 1972	15275
Memorandum dated Jan. 24, 1973, to the Commissioner, from Henry E. Simmons, M.D., M.P.H., Director, Bureau of Drugs, Food and Drug Administration	15275
Review of a bioavailability study by Harold R. Murdock, Ph. D., May 30, 1973	15277
Medical Officer's Review of New Drug Application No. 11-613 by Theresa T. Woo, M.D., May 30, 1973	15277
Letter dated Feb. 19, 1974, to Alda P. Truant, Ph. D., Pennwalt Corp., from Barrett Scoville, M.D., Deputy Director, Division of Neuropharmacological Drug Products, Food and Drug Administration	15278
Memorandum of conference dated Oct. 3, 1974, between Dr. W. Head, Dr. J. R. McGraw, Dr. F. Leaders, Dr. J. E. Giering, Pennwalt Corp., and Dr. B. Scoville, Dr. T. Hayes, Dr. H. Murdock, Dr. T. Woo, Mr. W. C. Crabbs, Food and Drug Administration	15278
Letter dated Apr. 10, 1975, to Peter E. Manni, Ph. D., Pennwalt Corp., from Barrett Scoville, M.D., Director, Division of Neuropharmacological Drug Products, Food and Drug Administration	15279
Supervisory review of review dated Feb. 17, 1976, by Thomas A. Hayes, M.D.	15279
Drug efficacy study of the National Academy of Sciences--National Research Council, NDA No. 10-093, Sept. 23, 1955	15280
Drug efficacy study of the National Academy of Sciences--National Research Council, NDA No. 11-613, May 14, 1959	15285